Future Integrative Medicine (FIM) is the official scientific journal of the Capital Medical University. It promotes future innovation in medicine by actively integrating the best of both traditional wisdom and modern scientific advancement. FIM publishes high-quality, peer-reviewed original research articles, reviews, opinions, commentaries, case reports, study protocols, and letters covering a wide range of topics that integrates conventional medicine and traditional medicine, as well as alternative/complementary medicine. FIM recognizes that the modernization and future-proofing of traditional medicine fundamentally rely on the rigorous application of modern medical science and cutting-edge biomedical technologies. Thus, FIM also welcomes studies applying advanced techniques (including molecular biology, biochemistry, immunology, genomics, proteomics, advanced imaging, and systems biology) to dissect the underlying mechanisms of traditional or alternative medicine. Topics of special interest are outlined as follows:  

• Application of modern medical diagnostics and therapeutics within integrative frameworks.
• Evidence-based studies investigating drugs, traditional Chinese medicine, dietary supplements, and other non-drug treatments.
• Efficacy and safety-guided biomarker research employing advanced analytical techniques.
• Epidemiologic studies
• Efficacy-associated pharmacological characterization
• Pharmacologically active substances and quality control
• Molecular mechanism studies (computational and in silico studies will not be accepted unless followed by experimental validation conducted with robust modern laboratory techniques).

Future Integrative Medicine (FIM) adopts open access publishing model, and all articles are distributed under the terms of the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/). Under this license, anyone may copy, distribute, or reuse these articles for non-commercial purposes, provided the original work is properly cited. Manuscripts submitted for publication in an open access journal are subject to the same rigorous peer-review and quality control as in scholarly subscription journals.

FIM recognizes the distinct advantages of using an open access publication model to timely disseminate innovative and important research findings. Unrestricted free access to our publications is anticipated to foster intellectual discourse across geographic and disciplinary boundaries. To support the success of our open access approach, we ensure the integrity and high quality of research published in our journal by practicing a rigorous peer review process and by following strict guidelines for ethics in publication and in conduct of the scientific process.

All manuscripts submitted to FIM must meet the following criteria for publication:

• Topics with timely relevance to the general field or specialties in basic and clinical medicine;
• A must-have section of “hypothesis/ future direction/ prospect/ prediction” included for all research and review articles;
• Results and findings that have not been previously published elsewhere;
• Research performed with adherence to accepted global standards for ethics in the scientific process;
• Ethical reporting of data to protect the rights and privacy of study participants;
• Appropriate statistical analyses, with sufficient descriptions of all statistical methods used;
• Conclusions supported by the data presented;
• All funding sources and their roles cited;
• For clinical trials, the registration number cited;
• Manuscript written in standard American (US) English and formatted according to the journal-specific guidelines;
• No instances of textual plagiarism, including ‘text recycling/self-plagiarism”.

FIM currently publishes 4 issues a year, in March, June, September and December.

FIM follows an open access publishing model. Revenue is generated through article processing charges, permissions, and reprints. Currently, the publication costs are covered by the publisher.